Lineage Cell Therapeutics FY2024 EPS Lifted by HC Wainwright

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Stock analysts at HC Wainwright boosted their FY2024 earnings per share estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Wednesday, December 4th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.11) for the year, up from their prior forecast of ($0.14). HC Wainwright has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.09) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics' Q4 2024 earnings at ($0.03) EPS, FY2025 earnings at ($0.04) EPS, FY2026 earnings at $0.00 EPS, FY2027 earnings at ($0.05) EPS and FY2028 earnings at ($0.05) EPS.

LCTX has been the subject of a number of other reports. D. Boral Capital lowered their price objective on shares of Lineage Cell Therapeutics from $3.00 to $2.00 and set a "buy" rating for the company in a research report on Wednesday, November 20th. Craig Hallum began coverage on shares of Lineage Cell Therapeutics in a report on Tuesday, August 20th. They set a "buy" rating and a $4.00 price target for the company.

Lineage Cell Therapeutics Price Performance

LCTX traded up $0.01 during trading on Friday, hitting $0.59. 1,107,976 shares of the stock traded hands, compared to its average volume of 1,013,778. The company has a market cap of $110.62 million, a P/E ratio of -4.88 and a beta of 1.16. Lineage Cell Therapeutics has a twelve month low of $0.50 and a twelve month high of $1.61.

Institutional Investors Weigh In On Lineage Cell Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Defender Capital LLC. grew its holdings in shares of Lineage Cell Therapeutics by 0.6% during the third quarter. Defender Capital LLC. now owns 5,002,198 shares of the company's stock valued at $4,528,000 after buying an additional 29,223 shares during the last quarter. Raffles Associates LP boosted its stake in Lineage Cell Therapeutics by 3.4% during the 3rd quarter. Raffles Associates LP now owns 4,507,781 shares of the company's stock valued at $4,081,000 after purchasing an additional 150,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in Lineage Cell Therapeutics by 2.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company's stock worth $3,331,000 after purchasing an additional 83,274 shares in the last quarter. State Street Corp raised its stake in shares of Lineage Cell Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,608,352 shares of the company's stock worth $2,361,000 after purchasing an additional 45,483 shares during the last quarter. Finally, MAI Capital Management lifted its holdings in shares of Lineage Cell Therapeutics by 2.2% in the third quarter. MAI Capital Management now owns 1,674,679 shares of the company's stock valued at $1,516,000 after purchasing an additional 35,907 shares in the last quarter. Institutional investors and hedge funds own 62.47% of the company's stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.